Novak Novak P P Kovacech Kovacech B B Katina Katina S S ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease Nat Aging Nat Aging 2021 2021 1 1 521 521 534 534 10.1038/s43587-021-00070-2 10.1038/s43587-021-00070-2. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.